Last reviewed · How we verify
human biphasic insulin
At a glance
| Generic name | human biphasic insulin |
|---|---|
| Also known as | Julphar Insulin 30/70 |
| Sponsor | Julphar Gulf Pharmaceutical Industries |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Influence of the Fruit Matrix on Glucose and Insulin Responses After the Intake of Orange Juice in Healthy Human Males (NA)
- Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus (PHASE4)
- Embryo Developmental Potential in a Novel 2-step IVM System (NA)
- Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus. (PHASE3)
- Comparison of Two Biphasic Insulin Regimens (NA)
- Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process in Healthy Japanese (PHASE1)
- Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction
- NovoLet® Surveillance Study on Using Human Insulin System in Indonesia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- human biphasic insulin CI brief — competitive landscape report
- human biphasic insulin updates RSS · CI watch RSS
- Julphar Gulf Pharmaceutical Industries portfolio CI